Back to Search Start Over

NO to breast: when, why and why not?

Authors :
Pervin S
Chaudhuri G
Singh R
Source :
Current pharmaceutical design [Curr Pharm Des] 2010; Vol. 16 (4), pp. 451-62.
Publication Year :
2010

Abstract

Nitric oxide is a pleiotropic ancestral molecule, which elicits beneficial effect in many physiological settings but is also tenaciously expressed in numerous pathological conditions, particularly breast tumors. Nitric oxide is particularly harmful in adipogenic milieu of the breast, where it initiates and promotes tumorigenesis. Epidemiological studies have associated populations at a greater risk for developing breast cancer, predominantly estrogen receptor positive tumors, to express specific polymorphic forms of endothelial nitric oxide synthase, that produce sustained low levels of nitric oxide. Low sustained nitric oxide generates oxidative stress and inflammatory conditions at susceptible sites in the heterogeneous microenvironment of the breast, where it promotes cancer related events in specific cell types. Inflammatory conditions also stimulate inducible nitric oxide synthase expression, which dependent on the microenvironment, could promote or inhibit mammary tumors. In this review we re-examine the mechanisms by which nitric oxide promotes initiation and progression of breast cancer and address some of the controversies in the field.

Details

Language :
English
ISSN :
1873-4286
Volume :
16
Issue :
4
Database :
MEDLINE
Journal :
Current pharmaceutical design
Publication Type :
Academic Journal
Accession number :
20236074
Full Text :
https://doi.org/10.2174/138161210790232130